Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
| Reel/Frame: | 049749/0977 | |
| Pages: | 10 |
| | Recorded: | 07/15/2019 | | |
| Attorney Dkt #: | GANYMED |
| Conveyance: | ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). |
|
|
Total properties:
6
|
|
|
|
Patent #:
|
|
Issue Dt:
|
04/03/2018
|
Application #:
|
15133783
|
Filing Dt:
|
04/20/2016
|
|
Publication #:
|
|
Pub Dt:
|
08/04/2016
| | | | |
|
Title:
|
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
02/27/2018
|
Application #:
|
15206039
|
Filing Dt:
|
07/08/2016
|
|
Publication #:
|
|
Pub Dt:
|
12/08/2016
| | | | |
|
Title:
|
CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
11/24/2020
|
Application #:
|
15866139
|
Filing Dt:
|
01/09/2018
|
|
Publication #:
|
|
Pub Dt:
|
05/24/2018
| | | | |
|
Title:
|
CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
08/18/2020
|
Application #:
|
15885454
|
Filing Dt:
|
01/31/2018
|
|
Publication #:
|
|
Pub Dt:
|
06/14/2018
| | | | |
|
Title:
|
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
02/16/2021
|
Application #:
|
16028210
|
Filing Dt:
|
07/05/2018
|
|
Publication #:
|
|
Pub Dt:
|
01/10/2019
| | | | |
|
Title:
|
ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
10/18/2022
|
Application #:
|
16275111
|
Filing Dt:
|
02/13/2019
|
|
Publication #:
|
|
Pub Dt:
|
06/06/2019
| | | | |
|
Title:
|
METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
|
|
|
Assignee
|
|
|
|
|
| AN DER GOLDGRUBE 12 |
| MAINZ, GERMANY 55131 |
|
|
Correspondence name and address
|
| |
NEAL, GERBER & EISENBERG LLP
|
| |
TWO NORTH LASALLE STREET
|
| |
SUITE 1700
|
| |
CHICAGO, IL 60602
|
Search Results as of:
06/16/2024 12:05 AM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
| 
